Results 81 to 90 of about 2,680 (197)

Switching Residues: A Platform for the Synthesis of Fidaxomicin Antibiotics

open access: yesAngewandte Chemie International Edition, Volume 64, Issue 7, February 10, 2025.
Switching residues: Adding new substituents to natural products increases their molecular weight and often their lipophilicity. We developed a Pd‐catalysed protocol to directly replace the rhamnoside‐arene fragment of the antibiotic fidaxomicin with simple amines in 1 step from the unprotected natural product.
Erik Jung   +14 more
wiley   +1 more source

Measuring outcomes in complicated intra-abdominal infections [PDF]

open access: yes, 2020
Purpose of review: Complicated intra-abdominal infections (cIAIs) are associated with significant morbidity and mortality. Clinical trials should help guide and improve the management of cIAIs.
Ahmed, S, Kirby, A, Wilcox, M
core   +1 more source

Unusual Presentation of Mycobacterium abscessus Thigh Mass: A Case Report

open access: yesCase Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Mycobacterium abscessus is a rapidly growing non‐tuberculous Mycobacterium (NTM) primarily associated with pulmonary infections, particularly in individuals with underlying lung conditions. While soft tissue infections are less common, their incidence has been increasing.
Ryan J. Blake   +5 more
wiley   +1 more source

Carbapenem‐Resistant Klebsiella pneumoniae Isolated From a Patient in a Midwestern U.S. Hospital With a History of Indian Travel: Therapeutic Strategies and Clinical Outcomes

open access: yesCase Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Carbapenemases have had increasing prevalence within the United States and worldwide. Here, we present a case of carbapenem‐resistant Klebsiella pneumoniae (CRKP) which is unique due to the rarity of multiple mechanisms of resistance within the Klebsiella pneumoniae harboring New Delhi metallo‐β‐lactamases (NDM), oxacillinase‐48 (OXA‐48)‐like, and ...
Christopher Phan   +6 more
wiley   +1 more source

Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022

open access: yesMicrobiology Spectrum
Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical and microbiological outcomes in addition to associated adverse effects of eravacycline used in U.S. hospitals. Real-
Ashlan J. Kunz Coyne   +31 more
doaj   +1 more source

Integrative analysis of outer membrane vesicles proteomics and whole-cell transcriptome analysis of eravacycline induced Acinetobacter baumannii strains

open access: yesBMC Microbiology, 2020
Background Acinetobacter baumannii is a multidrug-resistant (MDR) hazardous bacterium with very high antimicrobial resistance profiles. Outer membrane vesicles (OMVs) help directly and/or indirectly towards antibiotic resistance in these organisms.
DineshKumar Kesavan   +6 more
doaj   +1 more source

Dual role of ramR mutation in enhancing immune activation and elevating eravacycline resistance in Klebsiella pneumoniae

open access: yesiMetaOmics, Volume 1, Issue 2, December 2024.
The ramR mutations L58P and F165L weaken the binding between RamR and the ramA promoter, lifting RamR's suppression of ramA expression and resulting in the overexpression of the AcrAB‐TolC and OqxAB efflux pumps. Thus, these mutations enhance Klebsiella pneumoniae's resistance to eravacycline, up to 64‐fold.
Wei Yu   +8 more
wiley   +1 more source

Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2016
ABSTRACT We assessed the pharmacokinetic profile of eravacycline, a novel antibiotic of the tetracycline class, and determined the dose in an immunocompetent murine thigh infection model that would provide free-drug exposure similar to that observed in humans after the administration of 1 mg/kg intravenously (i.v.) every 12 h (q12h ...
Abrar K. Thabit   +2 more
openaire   +2 more sources

A Landscaping Assessment and Call‐to‐Action to Improve Access to Novel Reserve Antibiotics in 14 Low‐ and Middle‐Income Countries

open access: yesPublic Health Challenges, Volume 3, Issue 4, December 2024.
Antimicrobial resistance (AMR) is a major global health issue, especially in low‐ and middle‐income countries (LMICs). This study explores the AMR landscape in 14 LMICs, highlighting barriers to accessing novel Reserve antibiotics, such as affordability, safety and diagnostics.
Fabrizio Motta   +12 more
wiley   +1 more source

Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae

open access: yesJournal of Infection and Public Health
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a substantial healthcare challenge. This study assessed the in vitro efficacy of selected antibiotic combinations against CRKP infections.
Yu-Shan Huang   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy